Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Agenus: Encouraging Data on Prophage, But What is the Path Forward (AGEN, Buy, $3.28)

Introduction

On July 1, Agenus announced results from a non-randomized, phase 2 study of its therapeutic cancer vaccine Prophage in newly…
Read more…